• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 22, 2019

View Archived Issues

Biopharmas move into deep waters of massive data, high R&D potential

As a cautious swimmer slips slowly into the cool waters of a giant swimming pool so do biopharma executives: They tread into the murky abyss known as artificial intelligence (AI). Read More

AI propels med tech into new partnerships, new possibilities

Artificial intelligence (AI) is a technology that takes over when the human brain has reached its limit. For medical technology companies, it could help in the creation of more precise tools and devices that support diagnostic, therapeutic and surgical decisions. Instead of shooting an arrow into the sky, the bullseye target is clear, backed up by volumes of data and a machine learning algorithm designed to pinpoint the biomarker, the abnormality and the probability of success. Read More

Graybug raises $80M series C round for long-acting ocular meds

Graybug Vision Inc., a Redwood City, Calif.-based company developing therapies for eye diseases, has secured $80 million in series C financing to support moving its lead candidate, GB-102, into midstage studies in both wet age-related macular degeneration (AMD) and macular edema.  Read More

Oncorus has $79.5M chorus in oversubscribed series B

Oncorus Inc. plans to use its oversubscribed $79.5 million series B financing getting its lead candidate, ONCR-177, into the clinic early next year. Read More

'Commercial validation' for Themis' measles virus-based vaccine tech in Merck alliance

LONDON – Themis Bioscience GmbH has landed an exclusive licensing deal with Merck & Co. Inc., which simultaneously validates its measles virus-based vaccines platform and provides the means to extend the technology to new indications. Read More

South Korean firms Toolgen, Nsage to cooperate on gene-edited cell line R&D

South Korean biotech Toolgen Inc., based in Seoul, has signed an agreement with another Korean biomedical startup, Nsage Inc., based in Incheon, to cooperate on gene-edited cell line R&D and commercialization.  Read More

OIG: CMS is leaving millions in savings on Part B drugs on the table

It wouldn't take an act of the U.S. Congress or even an executive order for the Centers for Medicare & Medicaid Services (CMS) to save millions of dollars on Medicare Part B drugs. Read More

Other news to note

Tonix Pharmaceuticals Holding Corp., of New York, is collaborating with Massachusetts General Hospital to develop TNX-1500, a monoclonal antibody targeting CD154, for the prevention and treatment of organ transplant rejection. Read More

Financings

TFF Pharmaceuticals Inc., of Austin, Texas, filed to raise $22 million in an IPO by offering 4.4 million shares at a price of $5 each.  Read More

Regulatory front

Therapeuticsmd Inc., of Boca Raton, Fla., agreed to pay $200,000 in a civil penalty but admitted no wrongdoing in response to an SEC order charging it with violating Regulation FD based on selective disclosures about the company's dealings with the FDA.  Read More

Appointments and advancements

Marker Therapeutics Inc., of Houston, appointed Nadia Agopyan vice president of regulatory affairs. Read More

Clinical data for Aug. 21, 2019

Read More

Regulatory actions for Aug. 21, 2019

Read More

Transforming R&D and health care with artificial intelligence

The convergence of artificial intelligence (AI) and the health care sector was inevitable. The advent of machine-learning and deep-learning technologies capable of analyzing and synthesizing massive amounts of data with algorithms designed to mimic human-level decision-making seems a natural fit for an industry in dire need of greater efficiency. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 16, 2025.
  • Atai Therapeutics discovers new 5-HT2A receptor partial agonists

    BioWorld Science
    Atai Therapeutics Inc. has synthesized new tetrahydro pyridine-substituted indole and azaindoles acting as 5-HT2A receptor partial agonists reported to be useful...
  • PHD inhibitors reported in Akebia Therapeutics patent

    BioWorld Science
    Akebia Therapeutics Inc. has identified new derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate acting as prolyl 4-hydroxylase (PHD) inhibitors.
  • Woman  in military clothing talking with psychologist

    FDA wants more data for Otsuka’s sNDA in PTSD

    BioWorld
    The U.S. FDA is insisting that another study is needed to bolster the sNDA for Rexulti (brexpiprazole) from Otsuka Pharmaceutical Co. Ltd. in treating adults with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe